☢️ CPT 52250 — Cystourethroscopy With Insertion Of Radioactive Substance, With Or Without Biopsy Or Fulguration
Quick Reference
wRVU: 2.63 | Global Period: 000 | Assistant Payable: No | Bilateral Indicator: 0
Rule: CPT 52250 has a bilateral indicator of 0, meaning the 150% payment adjustment for bilateral procedures does not apply since the bladder is a single midline organ. An assistant surgeon is generally not permitted or payable for this endoscopic procedure.
📋 Clinical Description
CPT 52250 describes an endoscopic procedure where the urologist passes a cystourethroscope through the urethra into the bladder to perform a thorough visual examination of the urethral and bladder mucosa. Upon identifying the targeted area—typically a malignant neoplasm such as C67.9 (Malignant neoplasm of bladder, unspecified)—the provider inserts a radioactive substance (radiotracer or therapeutic isotope) directly into the bladder or the lesion for localized oncological treatment. During this same operative session, the provider may also take tissue samples (biopsy) or use electrocautery (fulguration) to destroy abnormal or suspicious tissue, but the primary defining element of this code is the insertion of the radioactive material.
This code is distinct from basic diagnostic cystourethroscopy because it includes active therapeutic intervention via radioactive insertion. It is related to, but distinct from, sibling codes like 52224 or 52240, which describe fulguration or resection of minor or large bladder tumors without the insertion of radioactive substances. When coding 52250, the biopsy and fulguration components are considered inclusive if performed on the same lesion or within the bladder during the encounter, meaning they should not be reported separately unless standard NCCI modifier rules apply for a distinctly separate anatomic site or encounter.
This procedure may be performed in the following clinical contexts:
- Localized Bladder Cancer Treatment — To deliver targeted internal radiation therapy directly to bladder tumors, minimizing systemic radiation exposure.
- Post-Resection Adjuvant Therapy — Following the resection of a tumor, radioactive material may be inserted to eradicate microscopic residual malignant cells and reduce recurrence risk.
- Palliative Care for Advanced Malignancy — Used to manage localized symptoms like severe hematuria associated with advanced bladder cancers that are not amenable to complete surgical resection.
- Concurrent Biopsy and Treatment — When a patient presents for a planned radioactive insertion and the provider concurrently discovers and biopsies a new suspicious lesion during the initial visual inspection.
🔬 Anatomical & Procedural Considerations
| Variant | Mechanism | Key Notes |
|---|---|---|
| Standard Insertion | The cystoscope provides direct visualization while a specialized catheter or applicator is passed through the working channel to deliver the liquid or encapsulated radioactive substance into the bladder cavity or directly into the targeted tumor tissue. | Strict handling protocols for radioactive materials must be documented. The specific radioisotope used and its precise dosage should be detailed in the operative report, as the supply of the radioactive agent may be reported with a separate HCPCS code. |
| With Concurrent Biopsy | Using cold cup biopsy forceps passed through the cystoscope, the provider extracts tissue samples from abnormal mucosal areas prior to or following the insertion of the radioactive substance. | Biopsy is inherently included in the descriptor for 52250. Coders should avoid reporting additional cystourethroscopy with biopsy codes for the same bladder encounter to prevent unbundling. |
| With Concurrent Fulguration | The provider uses an electrocautery loop or laser fiber passed through the cystoscope to burn and destroy small tumors or bleeding vessels in conjunction with the radioactive substance insertion. | Fulguration is bundled into this code’s primary service. The size of the tumor fulgurated does not change the code selection when the primary purpose includes the insertion of the radioactive substance. |
Clinical Pearl
The descriptor explicitly states “with or without biopsy or fulguration,” meaning you only report 52250 once, even if both a biopsy and fulguration are performed alongside the radioactive insertion. Ensure the specific HCPCS Level II code for the radioactive isotope/brachytherapy source is also reported if the practice incurred the cost of the material.
✅ Procedure Includes
- Cystourethroscopy (visual examination of the urethra, prostatic urethra in men, and bladder).
- Passing of catheters or applicators to deliver the radioactive substance.
- Insertion, instillation, or implantation of the radioactive material.
- Any biopsies taken from the bladder or urethra during the same operative session.
- Any fulguration (destruction) of bladder or urethral lesions during the same operative session.
- Routine irrigation of the bladder to clear blood clots or debris.
❌ Excludes / Do Not Report Together
| Code | Description | Relationship |
|---|---|---|
| 52000 | Cystourethroscopy (separate procedure) | Diagnostic cystourethroscopy is always bundled into therapeutic cystourethroscopy procedures. It should never be reported separately. |
| 52204 | Cystourethroscopy, with biopsy(s) | Biopsy is explicitly included in the descriptor for 52250 and cannot be coded in addition to it. |
| 52224 | Cystourethroscopy, with fulguration or treatment of MINOR lesion(s) | Fulguration of minor lesions is bundled into 52250 as the code descriptor encompasses fulguration. |
| 52234 | Cystourethroscopy, with fulguration and/or resection of SMALL bladder tumor(s) | Depending on NCCI edits, resection of a separate tumor may require careful modifier use, but routine fulguration of the same tumor is inclusive. |
Bundling Alert
CPT 52250 carries a global period of 000 days, meaning related preoperative and postoperative care on the day of the procedure is included in the reimbursement. Because the code description includes “with or without biopsy or fulguration,” it serves as a comprehensive code for that session. Appending modifier -59 or -XU to unbundle biopsy (52204) or minor fulguration (52224) codes during the same encounter poses a high audit risk and will typically result in claim denial unless a distinctly separate, unrelated procedure was performed on a different anatomic structure (e.g., upper urinary tract).
🌳 Code Tree — Surgery: Urinary System
CPT 50010-53899 Surgery: Urinary System
│
├── 52204-52318 Urethra and Bladder Transurethral Surgical Procedures
│ ├── 52224 Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) or treatment of MINOR (less than 0.5 cm) lesion(s) with or without biopsy (Global: 000)
│ ├── 52234 Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; SMALL bladder tumor(s) (0.5 up to 2.0 cm) (Global: 000)
│ ├── 52240 Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; LARGE bladder tumor(s) (Global: 000)
│ ├── ▶▶ 52250 ◀◀ Cystourethroscopy with insertion of radioactive substance, with or without biopsy or fulguration ← YOU ARE HERE (Global: 000)
│ ├── 52260 Cystourethroscopy, with dilation of bladder for interstitial cystitis; general or conduction (spinal) anesthesia (Global: 000)
│ └── 52265 Cystourethroscopy, with dilation of bladder for interstitial cystitis; local anesthesia (Global: 000)💰 RVU & Reimbursement Profile
| Component | Value |
|---|---|
| Work RVU | 2.63 |
| Global Period | 000 |
| Bilateral Indicator | 0 |
| Assistant Surgeon | 0 (Not permitted) |
| Co‑Surgeon | 0 (Not permitted) |
| Team Surgery | 0 (Not permitted) |
| PC/TC Split | 0 (No split) |
| Modifier -51 Exempt | No |
| Anesthesia | Base Units: 3 |
Bilateral Billing Rules
The bilateral indicator is 0 because the bladder is a midline organ. Modifiers -50, -RT, or -LT are entirely inappropriate for this code, and appending them will trigger automatic rejections. Payment is based on a single procedure regardless of how many areas within the bladder receive the radioactive insertion.
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -25 | Significant E/M | Apply to a separate Evaluation and Management service on the same day if a significant, separately identifiable evaluation was required beyond the usual pre/post-operative care of the cystourethroscopy. |
| -51 | Multiple Procedures | Apply if 52250 is performed during the same operative session as another independent, non-bundled procedure (e.g., a distinct ureteral procedure), provided 52250 is not the primary highest-valued code. |
| -52 | Reduced Services | Apply if the procedure was intentionally reduced or partially eliminated at the physician’s discretion (e.g., the cystoscope was inserted, but the radioactive substance could not be fully delivered due to anatomical obstruction). |
| -53 | Discontinued | Apply if the procedure was started but had to be terminated due to extenuating circumstances or circumstances that threatened the well-being of the patient (e.g., sudden severe patient instability during scope insertion). |
| -58 | Staged | Apply if the radioactive insertion was planned prospectively at the time of an initial, related procedure. |
| -59 | Distinct Service | Apply only when 52250 is performed at a distinctly separate encounter on the same day, or to identify it as a distinct procedural service from another code that would normally bundle, backed by robust documentation. |
| -78 | Return to OR | Apply if the patient must return to the operating room for a complication directly related to a prior procedure performed within the global period. |
| -79 | Unrelated Procedure | Apply if 52250 is performed during the postoperative global period of a completely unrelated procedure. |
🩺 Common ICD‑10‑CM Pairings
Primary Diagnosis Group
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| C67.9 | Malignant neoplasm of bladder, unspecified | Yes | The most common general code for bladder cancer when the specific wall or location is not pinpointed in the documentation. |
| C67.0 | Malignant neoplasm of trigone of bladder | Yes | Used when the neoplasm targeted for radioactive treatment is specifically located at the trigone. |
| C67.1 | Malignant neoplasm of dome of bladder | Yes | Used when the neoplasm is documented specifically at the dome of the bladder. |
| C67.2 | Malignant neoplasm of lateral wall of bladder | Yes | Used for tumors located on the lateral wall receiving the radioactive insertion. |
| C67.8 | Malignant neoplasm of overlapping sites of bladder | Yes | Appropriate when the tumor involves contiguous sites within the bladder that cannot be isolated to a single wall. |
Secondary Group
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| D09.0 | Carcinoma in situ of bladder | Yes | Used when the pathology identifies the lesion as non-invasive carcinoma in situ being treated with targeted internal radiation. |
| R31.0 | Gross hematuria | No | Often a presenting symptom of the bladder tumor; reportable if it is the primary reason for the encounter before a definitive malignancy diagnosis is established. |
Etiology / Complication
| ICD‑10 | Description | HCC? | Notes |
|---|---|---|---|
| Z85.51 | Personal history of malignant neoplasm of bladder | No | Used if the procedure is being performed prophylactically or to manage a localized recurrence in a patient with a known history of the disease. |
Coding Specificity Reminder
When coding for bladder cancer (C67.0 through C67.9), always ensure the operative report specifies the exact anatomical location within the bladder (e.g., trigone, dome, lateral wall, posterior wall) whenever possible to maximize specificity. Avoid defaulting to C67.9 if the operative note provides the specific site of the radioactive substance insertion.
🏥 MS‑DRG Considerations
When CPT 52250 is performed in an inpatient setting, it may influence the MS-DRG grouping within the Major Diagnostic Category 11 (Diseases and Disorders of the Kidney and Urinary Tract). It typically groups to surgical MS-DRGs such as 668, 669, or 670 (Transurethral Procedures with or without MCC/CC). However, this procedure is predominantly performed in the outpatient hospital or ambulatory surgery center setting. Always verify Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) related to brachytherapy or internal radiation therapy, as specific diagnosis codes and prior authorizations are frequently mandated by MACs to justify the medical necessity of the radioactive material supply.
🔧 ICD‑10‑PCS Equivalents
| PCS Code | Full Description | Modality |
|---|---|---|
| 0T7C8ZZ | Dilation of Bladder, Via Natural or Artificial Opening Endoscopic | Endoscopy |
| 0T7B8ZZ | Dilation of Urethra, Via Natural or Artificial Opening Endoscopic | Endoscopy |
| 0TBB8ZX | Excision of Urethra, Via Natural or Artificial Opening Endoscopic, Diagnostic | Endoscopy |
| 0TBC8ZX | Excision of Bladder, Via Natural or Artificial Opening Endoscopic, Diagnostic | Endoscopy |
PCS Character Analysis
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 0 | Medical and Surgical. |
| 2 | Body System | T | Urinary System. |
| 3 | Root Operation | B | Excision: Cutting out or off, without replacement, a portion of a body part (if biopsy is performed). |
| 4 | Body Part | C | Bladder: The specific organ being visualized and treated. |
| 5 | Approach | 8 | Via Natural or Artificial Opening Endoscopic: The cystoscope enters through the urethra. |
| 6 | Device | Z | No Device: No device is left permanently in place from the surgical excision standpoint. |
| 7 | Qualifier | X | Diagnostic: Used if the excision was for a biopsy (otherwise Z for no qualifier). |
Root Operation Comparison
Excision vs. Destruction: If a biopsy is taken, the root operation is Excision (with the Diagnostic qualifier). If the lesion is only fulgurated (burned), the root operation is Destruction.
Introduction: For the placement of the radioactive substance, a separate PCS code from the Radiation Oncology section (Section C) or Administration section (Section 3) may be required to capture the delivery of the therapeutic isotope.
📝 Coding Examples
Example 1
Clinical Scenario: A 68-year-old male with a known history of carcinoma in situ of the bladder presents to the outpatient surgical center. The urologist passes a cystoscope through the urethra and identifies a localized area of recurrent abnormal tissue on the lateral wall of the bladder. The surgeon uses biopsy forceps to take a sample of the abnormal tissue. Following the biopsy, a specialized applicator is passed through the cystoscope, and a radioactive isotope is inserted directly into the tumor bed. The bladder is irrigated, and the scope is removed.
| Field | Code | Rationale |
|---|---|---|
| CPT | 52250 | Captures the cystourethroscopy with the insertion of the radioactive substance. The biopsy is explicitly bundled in the code descriptor. |
| PDx | D09.0 | Carcinoma in situ of the bladder represents the primary medical reason for the targeted radiation treatment. |
Note
Example 2
Clinical Scenario: A 72-year-old female presents for targeted treatment of a malignant neoplasm on the dome of the bladder. The urologist inserts the cystoscope, visualizes the tumor, and immediately performs fulguration using electrocautery to debulk the lesion. Once hemostasis is achieved, a radioactive seed is implanted into the remaining tumor base via the cystoscope.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 52250 | Captures the primary procedure of inserting the radioactive substance via cystourethroscopy. |
| PDx | C67.1 | Malignant neoplasm of the dome of the bladder. |
Warning
Example 3
Clinical Scenario: A patient undergoes a planned cystourethroscopy for the insertion of a radioactive substance to treat unspecified bladder cancer. During the procedure, the urologist successfully inserts the radioactive material. Additionally, the physician identifies a urethral stricture and performs a direct vision internal urethrotomy before completing the bladder treatment.
| Field | Code | Rationale |
|---|---|---|
| CPT | 52250 | Represents the primary procedure for the bladder cancer treatment. |
| CPT | 52270--51 | Represents the internal urethrotomy, which is a distinct procedure from the bladder treatment. Modifier -51 indicates multiple procedures. |
| PDx | C67.9 | Bladder cancer, unspecified. |
Note
Review NCCI edits closely; if the stricture was merely dilated to allow passage of the scope, it is bundled. However, a formal internal urethrotomy is generally separately reportable with the multiple procedure modifier.
⚠️ Common Coding Pitfalls
- Pitfall 1: Unbundling diagnostic cystoscopy. Reporting 52000 alongside 52250 is incorrect because the diagnostic visualization is inherently required to perform the therapeutic insertion.
- Pitfall 2: Coding separately for biopsies. Appending 52204 when the provider takes a tissue sample during the same session as the radioactive insertion violates the explicit descriptor of 52250.
- Pitfall 3: Coding separately for fulguration. Attempting to bill 52224 or 52234 for cauterizing the same lesion receiving the radioactive substance will result in denials.
- Pitfall 4: Applying bilateral modifiers. Using -50, -LT, or -RT on 52250 is an anatomic error because the bladder is a single, midline organ.
- Pitfall 5: Omitting the supply code. Failing to bill the appropriate Level II HCPCS code for the radioactive isotope or brachytherapy source means the facility will lose reimbursement for expensive therapeutic materials.
- Pitfall 6: Ignoring NCD/LCD guidelines. Neglecting to match the exact ICD-10-CM diagnosis codes required by local Medicare contractors for internal radiation therapies can lead to immediate medical necessity rejections.
📎 Sources
CPT 2026 Professional Edition, American Medical Association, 2025.
Medicare Physician Fee Schedule (MPFS) 2026, Centers for Medicare & Medicaid Services.
Sources listed above correspond to superscript citations throughout this note. Verify all Medicare payment figures against your current CMS PFS Lookup tool and applicable MAC LCD prior to claim submission. Please use the latest AAPC/AHIMA Coding Books to verify each code within this note.